Drug Interaction Report

MONITOR: Coadministration with cobicistat may increase the plasma concentrations of most HMG-CoA reductase inhibitors (i.e., statins) to varying degrees. Cobicistat is a potent inhibitor of CYP450 3A4 and can significantly increase exposure to statins that are primarily metabolized by the isoenzyme (e.g., atorvastatin, lovastatin, simvastatin). Cobicistat may also inhibit the OATP 1B1- and 1B3- mediated hepatic uptake of statins, thus even those that are not metabolized by CYP450 3A4 may be affected. High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.

MANAGEMENT: Caution is advised when statins are prescribed with cobicistat-containing regimens. The lowest starting dosage of the statin is recommended, then titrated as needed based on clinical response and tolerance. Some statins such as lovastatin and simvastatin are contraindicated for use with cobicistat. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.

ADJUST DOSING INTERVAL: Food enhances the absorption and oral bioavailability of darunavir administered in combination with low-dose ritonavir. The mechanism is unknown. When administered with food, the peak plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) of darunavir were approximately 30% higher than when administered in the fasting state. Darunavir exposure was similar for the range of meals studied. The total caloric content of the various meals evaluated ranged from 240 Kcal (12 grams fat) to 928 Kcal (56 grams fat).

MANAGEMENT: To ensure maximal oral absorption, darunavir coadministered with ritonavir should be taken with food. The type of food is not important.